Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD
In MASLD, statin therapy was associated with a dose-dependent PLC risk reduction. High-intensity therapy (simvastatin-equivalent > 40 mg daily) conferred substantial protection regardless of age, sex, insulin resistance, or cirrhosis, supporting a potential statin-based PLC chemoprevention in MASLD.
Authors
- Manal F. Abdelmalek (ORCID: https://orcid.org/0000-0002-5001-8618)
- Anna Mae Diehl (ORCID: https://orcid.org/0000-0003-1859-089X)
- Ayako Suzuki (ORCID: https://orcid.org/0000-0003-1824-1067)
- Jimmy T. Efird (ORCID: https://orcid.org/0000-0002-4890-5111)
- Amy M. Perkins (ORCID: https://orcid.org/0000-0001-9052-3558)
- Ruth Reeves (ORCID: https://orcid.org/0000-0003-4260-2707)
- Chad Dorn (ORCID: https://orcid.org/0000-0002-4886-6159)
- Georgia Sofia Karachaliou (ORCID: https://orcid.org/0000-0003-4091-3798)
- Timothy Arnold
- Mustafa R. Bashir
Institutions
- Duke University (US)
- University of Michigan (US)
- The Coordinating Center (US)
- VA Tennessee Valley Healthcare System (US)
- Office of the Assistant Secretary for Health (US)
- Mayo Clinic in Arizona (US)
- Duke Medical Center (US)
- Durham VA Medical Center (US)
- Duke University Hospital (US)
- Case Western Reserve University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-01
- DOI
- https://doi.org/10.3390/cancers18071132
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Duke University